Vaccine Composition Comprising Recombinant Protein for Preventing Swine Mycoplasma Infection

    公开(公告)号:US20190177375A1

    公开(公告)日:2019-06-13

    申请号:US16324827

    申请日:2017-08-14

    申请人: INNOVAC

    IPC分类号: C07K14/30 A61K39/02

    摘要: Provided are a recombinant protein for producing a swine Mycoplasma infection-preventing vaccine composition, and a swine Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection-preventing vaccine composition including the recombinant protein. When the recombinant proteins for the vaccine production in accordance with the present disclosure are added to the swine Mycoplasma infection-preventing vaccine composition, the immune response to the swine Mycoplasma hyopneumoniae and swine Mycoplasma hyorhinis strain and the immune response to the P97 protein are increased. As a result, the present vaccine exhibits a defensive effect superior to an existing commercially available vaccine. Therefore, the recombinant proteins for the vaccine production according to the present disclosure and the vaccine compositions using the recombinant proteins may effectively prevent diseases caused by the Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection, especially, swine Mycoplasma-derived pneumonia and swine Mycoplasma-derived arthritis.

    Anti-Mycoplasma spp. subunit vaccine
    6.
    发明授权
    Anti-Mycoplasma spp. subunit vaccine 有权
    抗支原体 亚单位疫苗

    公开(公告)号:US09561267B2

    公开(公告)日:2017-02-07

    申请号:US14765512

    申请日:2013-02-05

    摘要: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.

    摘要翻译: 本发明提供抗支原体属 亚单位疫苗,特别是适用于支原体属活性成分的蛋白质。 亚单位疫苗和由其制备的疫苗。 在实验中,证实蛋白质可以引发具有足够强度的免疫应答以避免支原体感染。 在猪里 疫苗可以包含上述蛋白质之一作为活性成分,或者可以包含两种或更多种蛋白质以形成鸡尾酒疫苗。 本发明的疫苗不仅比常规疫苗更安全,而且具有相当或甚至更好的免疫效果。

    MINIMAL BACTERIAL GENOME
    7.
    发明申请
    MINIMAL BACTERIAL GENOME 审中-公开
    最小细菌基因组

    公开(公告)号:US20150344837A1

    公开(公告)日:2015-12-03

    申请号:US14733743

    申请日:2015-06-08

    摘要: The present invention relates, e.g., to a minimal set of protein-coding genes which provides the information required for replication of a free-living organism in a rich bacterial culture medium, wherein (1) the gene set does not comprise the 100 genes listed in Table 2; and/or wherein (2) the gene set comprises the 382 protein-coding genes listed in Table 3 and, optionally, one of more of: a set of three genes encoding ABC transporters for phosphate import (genes MG410, MG411 and MG412; or genes MG289, MG290 and MG291); the lipoprotein-encoding gene MG185 or MG260; and/or the glycerophosphoryl diester phosphodiesterase gene MG293 or MG385.

    摘要翻译: 本发明涉及例如提供在富细菌培养基中复制自由活体的所需信息的蛋白质编码基因的最小集合,其中(1)基因组不包括所列出的100个基因 在表2中; 和/或其中(2)基因组包含表3中列出的382个蛋白质编码基因,以及任选地,一组编码ABC转运蛋白的三个基因(基因MG410,MG411和MG412;或 基因MG289,MG290和MG291); 编码脂蛋白的基因MG185或MG260; 和/或甘油磷酸二酯磷酸二酯酶基因MG293或MG385。

    IMMUNOGLOBULJIN-BINDING HUMAN MYCOPLASMA ANTIGENS AND METHODS OF USE THEREOF
    8.
    发明申请
    IMMUNOGLOBULJIN-BINDING HUMAN MYCOPLASMA ANTIGENS AND METHODS OF USE THEREOF 有权
    免疫组织化学人MYCOPLASMA抗体及其使用方法

    公开(公告)号:US20150246953A1

    公开(公告)日:2015-09-03

    申请号:US14415307

    申请日:2013-07-16

    IPC分类号: C07K14/30 C07K16/12 A61K39/02

    摘要: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.

    摘要翻译: 本文提供减轻患者或受试者的多发性骨髓瘤症状的方法,治疗患者或受试者中的多发性骨髓瘤的方法,以及在患有风险的患者中预防多发性骨髓瘤发展的方法,例如具有 具有未确定意义的单克隆丙种球蛋白病(MGUS),该方法包括施用有效治疗支原体感染的药剂。 本发明还涉及以高亲和力结合各种免疫球蛋白的新一类抗原MG281蛋白(也称为蛋白M),以及它们在纯化免疫球蛋白中的用途。 本发明还涉及使用MG281蛋白和类似物或衍生物分子来治疗自身免疫性疾病。 还提供了用于所公开的方法中的抗原和抗体,以及鉴定结合MG281蛋白的分子。

    IMMUNOREACTIVE ANTIGENS OF MYCOPLASMA HEAMOFELIS AND DIAGNOSTIC IMMUNOASSAY
    9.
    发明申请
    IMMUNOREACTIVE ANTIGENS OF MYCOPLASMA HEAMOFELIS AND DIAGNOSTIC IMMUNOASSAY 有权
    MYCOPLASMA HEAMOFELIS和诊断性免疫测定的免疫反应

    公开(公告)号:US20130210671A1

    公开(公告)日:2013-08-15

    申请号:US13879292

    申请日:2011-10-13

    IPC分类号: G01N33/569

    摘要: Compositions for use in diagnostic screens for Mycoplasma haemofelis are provided. In one embodiment an immunogenic peptide selected from SEQ ID NO: 1 to SEQ ID NO: 60, or a fragment thereof, is immobilized on a solid support and is used to detect the presence of Mycoplasma haemofelis antibodies in a patient bodily fluid. In accordance with one embodiment a method for detecting a Mycoplasma haemofelis infection in a feline species, is provided.

    摘要翻译: 提供了用于血支原体诊断筛选的组合物。 在一个实施方案中,将选自SEQ ID NO:1至SEQ ID NO:60的免疫原性肽或其片段固定在固体支持物上,并用于检测患者体液中存在支原体血型抗体。 根据一个实施方案,提供了一种用于检测猫科动物中支原体感染的方法。